Initial Manifestations of Congestive Heart Failure in Patients With NSTEACS

Initial Manifestations of Congestive Heart Failure in Patients With Non-ST-segment Elevation Acute Coronary Syndrome

Acute heart failure (HF) is a common complication of acute coronary syndrome (ACS) associated with poor prognosis. Diagnosis of congestive HF in patients with initial, non-severe symptoms and signs may be challenging and early stages of this complication may be missed. To assess severity of HF in patients with ACS Killip classification is widely used but it does not take into account mild manifestations of HF. Thus, patients without rales in the lungs and/or S3 will be labelled as Killip class 1. The aim of this study is to determine the frequency, risk factors, abilities for early diagnosis using routine medical evaluation and clinical significance of subclinical and mildly symptomatic congestive HF in patients with ACS without persistent ST-segment elevation (NSTEACS).

The study will include 200 patients with NSTEACS without history of severe HF and overt signs of congestion at presentation. Presence and severity of dyspnea (according to Likert ans Visual analog scales), physical signs of heart failure (respiratory rate, distention of jugular veins, S3), peripheral oxygen saturation by pulse oximetry, heart rate and signs of ischemia on ECG, signs of congestion according to lung and vena cava inferior ultrasound and chest X-Ray/CT as well as levels of NT-proBNP, hsTn, CRP and FABP at presentation will be evaluated. Presence and severity of dyspnea, physical signs of heart failure, oxygen saturation, heart rate and signs of ischemia on ECG, lung and vena cava inferior ultrasound will be re-assessed after 6, 12 and 24 hours. During hospitalization occurrence or worsening of clinical HF. Clinical events will be followed up to 12 months after hospitalization.

Study Overview

• Status: Active, not recruiting
• Conditions: Acute Heart Failure, Non-ST-segment Elevation Acute Coronary Syndrome

• Study Type: Observational
• Enrollment (Estimated): 200

Contacts and Locations

Study Locations

• Russian Federation
  • Moscow, Russian Federation, 101990
    • National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Health of the Russian Federation and City clinical hospital named after A. K. Eramishantsev, Moscow, Russia, 129327

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

Patients with ACS without persistent ST-segment elevation without history of severe HF and clinical signs of congestion at presentation

Description

Inclusion Criteria:

• Patients hospitalized to the cardiac intensive care unit with ACS without persistent ST-segment elevation
• Signed informed consent

Exclusion Criteria:

• ACS with persistent ST-segment elevation
• High probability of absence of ACS
• Congestive rales in the base of lungs, cardiac asthma, pulmonary edema, cardiogenic shock, obvious edema, anasarca
• History of severe chronic heart failure (III-IV NYHA class, obvious edema, anasarca)
• Continuous use of loop diuretics

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Worsening of HF from enrollment to 24 hours	Worsening of HF is stated if at least one of following is present; ≥1 point increase of dyspnea according to 5-point Likert score: 1=not short of breath, 2=mildly short of breath, 3=moderately short of breath, 4=severely short of breath, 5=very severely short of breath.; Appearance/increase of jugular vein distension (if starting to be seen in patients lying horizontally or increasing degree of head of bed elevation for its disappearance).; Appearance of S3 gallop.; Appearance of congestive rales in the lungs.; Appearance of peripheral oedema related to HF.; Intravenous administration of diuretics/vasodilators due to clinical deterioration of HF.	from enrollment up to 24 hours

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Changes severity of congestion according to lung and vena cava inferior ultrasound from enrollment to 24 hours after initial assessment at presentation		from enrollment up to 24 hours
Composite of death, (re)myocardial infarction, stroke or hospitalisation for 12 months		up to 12 months
Composite of death, (re)infarction, stroke or worsening of HF from enrollment to discharge from the hospital	Worsening of HF is stated if at least one of following is present; Appearance of congestive rales in the lungs.; Appearance of peripheral oedema related to HF.; Intravenous administration of diuretics/vasodilators due to clinical deterioration of HF.	from admission to discharge or death during reference hospitalization, assessed up to 90 days

Collaborators and Investigators

• Sponsor: National Medical Research Center for Therapy and Preventive Medicine
• Collaborators: Clinical City Hospital named after A. K. Eramishantsev of Moscow Department of Healthcare

Study record dates

Study Major Dates

• Study Start (Actual): January 30, 2020
• Primary Completion (Actual): May 2, 2023
• Study Completion (Estimated): August 28, 2024

Study Registration Dates

• First Submitted: February 1, 2021
• First Submitted That Met QC Criteria: February 1, 2021
• First Posted (Actual): February 4, 2021

Study Record Updates

• Last Update Posted (Actual): December 1, 2023
• Last Update Submitted That Met QC Criteria: November 30, 2023
• Last Verified: November 1, 2023

More Information

Terms related to this study

• Keywords: acute heart failure, congestive heart failure, non-ST-segment elevation acute coronary syndrome, lung ultrasound, vena cava inferior ultrasound
• Additional Relevant MeSH Terms: Pathologic Processes; Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Vascular Diseases; Disease; Heart Failure; Syndrome; Acute Coronary Syndrome
• Other Study ID Numbers: 7

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No